Doravirine/lamivudine/tenofovir

Doravirine/lamivudine/tenofovir (brand name Delstrigo) is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[2][4] It contains doravirine, lamivudine, and tenofovir disoproxil.[5][4] In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018.[5][6][7]

Doravirine/lamivudine/tenofovir
Combination of
DoravirineNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleotide reverse transcriptase inhibitor
Clinical data
Trade namesDelstrigo
Other namesMK-1439A
AHFS/Drugs.comMonograph
MedlinePlusa618049
License data
ATC code
Legal status
Legal status
Identifiers
KEGG

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.